WaveMan
WaveMan · Company
AURX · Nuo Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AURX Nuo Therapeutics (AURX) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001091596
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $242.5K priced

What the filings say about AURX

Insiders, 180 days
+$9.5K net bought
1 buyer

Nuo Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Nuo Therapeutics, Inc. insiders bought a net $9.5K of stock across 17 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
JORDEN DAVID EMERSON
CEO/CFO
BUY
2026-08-31 SECtraded 2026-08-28
7,984
$8.7K
+14.0%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Aug 27, 2026.
  • The trade is 0.4% of the 2,070,000 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO/CFO JORDEN DAVID EMERSON bought about $8.7K of AURX on Aug 28, 2026, the largest insider purchase at the company since 2025.
JORDEN DAVID EMERSON
CEO/CFO
BUY
2026-08-31 SECtraded 2026-08-27
789
$844
+14.0%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Nov 28, 2025.
  • The trade is 0.0% of the 2,062,016 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO/CFO JORDEN DAVID EMERSON bought about $844 of AURX on Aug 27, 2026, the largest insider purchase at the company since 2025.
JORDEN DAVID EMERSON
CEO/CFO
SELL
2025-12-03 SECtraded 2025-11-28
200,000
$300.0K
-42.5%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Nov 9, 2022.
  • The trade is 10.3% of the 1,946,755 shares held after it.
  • No other insider sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO/CFO JORDEN DAVID EMERSON sold about $300.0K of AURX on Nov 28, 2025, the largest insider sale at the company on our record.
SHEEDY CHARLES E
BUY
2025-08-01 SECtraded 2025-07-30
133,333
$200.0K
-18.8%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Sep 18, 2024.
  • +121.9% median (+116722.6% mean) 90-day return after 6 previous buys.
  • The trade is 1.2% of the 11,570,833 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider SHEEDY CHARLES E bought about $200.0K of AURX on Jul 30, 2025, the largest insider purchase at the company since 2022.
SHEEDY CHARLES E
BUY
2024-09-19 SECtraded 2024-09-18
125,000
$93.8K
+136.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 20, 2024.
  • +62.0% median (+140030.8% mean) 90-day return after 5 previous buys.
  • The trade is 1.1% of the 11,437,500 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider SHEEDY CHARLES E bought about $93.8K of AURX on Sep 18, 2024, the largest insider purchase at the company since 2023.
17 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 12 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$9.5K over 180 days
+$9.5K over 90 days
more than 66% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+142.7% year over year
more than 94% of Medical Devices
Margin
-75.8% net margin
below 76% of Medical Devices
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AURX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-45.8%12M
-68%-43%-18%+7%2025-102025-122026-022026-042026-062026-082026-10 2025-11-28 · JORDEN DAVID EMERSON sold $300.0K2026-08-28 · JORDEN DAVID EMERSON bought $8.7K2026-08-27 · JORDEN DAVID EMERSON bought $844
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AURX: institutional holders (13F)

13F holdings, latest reported quarter
Ancora Advisors LLC
4,700 sh
$4.3K

Congress trades in AURX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AURX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $9.5K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

AURX financials

Revenue growth
+142.7%
XBRL, annual
Net margin
-75.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-38.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$2.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
n/a
no debt to cover
Return on equity
n/a
average equity is zero or negative
Return on assets
-101.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-241.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$62.5M
market value at close 2026-10-26 on 2026-08-12 shares, plus long-term debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
FCF yield
-3.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$3.3M$1.4M$608.5K$112.2K
Gross profit$2.2M$1.1M$482.4K$93.0K
Operating income-$2.5M-$2.5M-$3.2M-$3.3M
Net income-$2.5M-$2.3M-$3.2M-$3.2M
Operating cash flow-$865.0K-$2.2M-$3.2M-$3.7M
Cash$548.9K$283.7K$928.7K$2.1M
SEC XBRL, fiscal years, as known on 2026-10-28

AURX Stock Sonar score 4/7 axes

Find similar shapesCompare

AURX ranks highest on risk and compliance (95th percentile) and growth (94th), and lowest on profitability (12th), among Medical Devices peers.

Profitability
12
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-101.0% · 18 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-241.8% · 7 pct, sector of 188
Growth
94
Inputs
  • Revenue growth, YoY+142.7% · 94 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
58
Inputs
  • Net Form 4 buying (codes P and S), 180d$10K · 65 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Risk and compliance
95
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.2% · 89 pct, sector of 198
3 not measured: Financial health, Institutional and government, US patents
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; no debt to cover
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AURX filings, in plain words

Are Nuo Therapeutics insiders buying or selling AURX?

In the 180 days to 2026-10-28, Nuo Therapeutics insiders were net buyers, a net $9.5K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Nuo Therapeutics insiders were net buyers of AURX, a net $9.5K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies